COVID19 . El Tratamiento ORAL Molnupiravir ( MERCK ) Elimina el Virus SARS_Cov_2 Infeccioso al Tercer Día de Iniciar la Terapia, Según un Estudio Que se Presentará en el Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas ( ECCMID ) .

 MOLNUPIRAVIR ES CAPAZ DE ELIMINAR COMPLETAMENTE EL COVID-19 DE UN PACIENTE EN SOLO TRES DÍAS .

Molnupiravir is An Orally Administered Antiviral Drug That Fights Covid-19. According to a Studi By The Pharmaceutical Company MSD, a Trade Name of Merck, The Drug's Manufacturer, Molnupiravir Eliminates actively Infectious Covid19 on The Third Day of Initiating Therapy.

What Is Molnupiravir, The 3-Day COVID Drug ? .

The Drug, according to the World Health Organisation (WHO), should only be administered to "patients with non-severe covid-19 who are at maximum risk of hospitalisation", and in no case "to children or pregnant women". 

The WHO explains that the drug is usually used in "people who have not been vaccinated against covid-19, the elderly, immunocompromised people and people with chronic diseases".

The WHO announced the inclusion of this antiviral in its list of recommended treatments for covid-19 on 3 March 2022, and it has also been approved for emergency use in countries including the United States, the United Kingdom, Australia and Japan.

The study, which will be presented at ECCMID next week but was advanced in a statement on 2 April, indicates that participants underwent PCR testing to determine SARS-CoV-2 RNA viral loads from nasopharyngeal swabs collected on days 1 (baseline), 3, 5 (end-of-treatment visit), 10, 15 and 29. 

On day 3 of treatment, none of the 92 participants who received molnupiravir had detected infectious SARS-CoV-2, compared to 21.8% (20 out of 96) of participants taking a placebo.